Asceneuron CEO Dirk Beher to Speak at Alzheimer's Association International Conference
Dr Dirk Beher will discuss the topic "O-GlcNAcase Inhibitors as Therapies for Tauopathies" and will provide an update on the current status of Asceneuron'sO-GlcNAcase inhibitor research and clinical pipeline.
- Dr Dirk Beher will discuss the topic "O-GlcNAcase Inhibitors as Therapies for Tauopathies" and will provide an update on the current status of Asceneuron'sO-GlcNAcase inhibitor research and clinical pipeline.
- The Alzheimer's Association International Conference is the largest and most influential international meeting dedicated to advancing dementia science.
- Asceneuron is a clinical stage biotech company focused on the development of orally bioavailable therapeutics for debilitating neurodegenerative disorders with high unmet medical need.
- Asceneuron has two clinical stage small molecule O-GlcNAcase inhibitors in development for the treatment of proteinopathies including Parkinson's Disease, Alzheimer's disease and related disorders.